Expression profiling on subclasses of primary parotid gland carcinomas.

Autor:	Meinrath J; Institute of Pathology, University Hospital of Cologne, Cologne, Germany., Haak A; Department of Pathology, University of Halle, Halle, Germany., Igci N; Institute of Pathology, University Hospital of Cologne, Cologne, Germany., Dalvi P; Institute of Pathology, University Hospital of Cologne, Cologne, Germany.; Center for Molecular Medicine, University of Cologne, Cologne, Germany., Arolt C; Institute of Pathology, University Hospital of Cologne, Cologne, Germany., Meemboor S; Institute of Pathology, University Hospital of Cologne, Cologne, Germany.; Center of Integrative Oncology, University Hospital of Cologne, Cologne, Germany., Siebolts U; Department of Pathology, University of Halle, Halle, Germany., Eischeidt-Scholz H; Institute of Pathology, University Hospital of Cologne, Cologne, Germany., Wickenhauser C; Department of Pathology, University of Halle, Halle, Germany., Grünewald I; Department of Pathology, University Hospital of Münster, Münster, Germany., Drebber U; Institute of Pathology, University Hospital of Cologne, Cologne, Germany.; Center of Integrative Oncology, University Hospital of Cologne, Cologne, Germany., Büttner R; Institute of Pathology, University Hospital of Cologne, Cologne, Germany.; Center for Molecular Medicine, University of Cologne, Cologne, Germany.; Center of Integrative Oncology, University Hospital of Cologne, Cologne, Germany., Quaas A; Institute of Pathology, University Hospital of Cologne, Cologne, Germany.; Center of Integrative Oncology, University Hospital of Cologne, Cologne, Germany., Klußmann JP; Center of Integrative Oncology, University Hospital of Cologne, Cologne, Germany.; Department of Otorhinolaryngology, Head and Neck Surgery, University of Cologne, Cologne, Germany., Odenthal M; Institute of Pathology, University Hospital of Cologne, Cologne, Germany.; Center for Molecular Medicine, University of Cologne, Cologne, Germany.; Center of Integrative Oncology, University Hospital of Cologne, Cologne, Germany., Beutner D; Department of Otorhinolaryngology, Head and Neck Surgery, University of Cologne, Cologne, Germany.; Department of Otorhinolaryngology, Head and Neck Surgery, University Medical Center Göttingen, Göttingen, Germany., Meyer M; Department of Otorhinolaryngology, Head and Neck Surgery, University of Cologne, Cologne, Germany.; Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Essen, University Duisburg-Essen, Duisburg, Germany.
Jazyk:	angličtina
Zdroj:	Oncotarget [Oncotarget] 2020 Nov 10; Vol. 11 (45), pp. 4123-4137. Date of Electronic Publication: 2020 Nov 10 (Print Publication: 2020).
DOI:	10.18632/oncotarget.27797
Abstrakt:	Introduction: The underlying molecular mechanisms of parotid gland carcinomas (PGC) are still unknown. Knowledge about the tumor-driving signaling pathways is necessary either for diagnostics or developing new therapeutic options in this heterogeneous and rare entity. Material and Methods: 94 matching RNA formalin-fixed and paraffin-embedded tissue samples from PGC and the corresponding non-tumor area, RNA quality and quantity were sufficient for gene expression profiling of 770 genes using the NanoString's nCounter technology. Oncogenic and tumor suppressor genes were examined in the three common PGC tumor entities: adenoid cystic carcinoma (ACC), adenocarcinoma NOS (AC-NOS), and mucoepidermoid carcinoma (MEC). Results: Expression profiling and subsequent hierarchical cluster analysis clearly differentiated between non-tumor gland tissue samples and PGC. In addition expression pattern of all three entities differed. The extensive pathway analysis proved a prominent dysregulation of the Wnt signaling pathway in the three PGC entities. Moreover, transcript upstream analysis demonstrated a pronounced activation of the PI3K pathway in ACC and MEC. Discussion: Our findings revealed divergent molecular expression profiles in MEC, ACC and AC-NOS that are presently studied for their potential application in PGC diagnostics. Importantly, identification of Wnt and PI3K signaling in PGC revealed novel options of PGC therapy. Competing Interests: CONFLICTS OF INTEREST Authors have no conflicts of interest to declare. (Copyright: © 2020 Meinrath et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu